News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Exelixis, Inc. Drug Shows Promise in Brain Cancer-Study
May 15, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- An experimental drug being developed by Exelixis Inc and Bristol-Myers Squibb Co was shown to shrink brain tumors in some patients, according to interim results from a mid-stage study of the drug, known as XL184.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Phase III
Exelixis, Inc.
MORE ON THIS TOPIC
Cardiovascular disease
Ionis’ Tryngolza ‘Game-Changing in Lowering Triglycerides, Cementing Case for FDA Filing
November 10, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy
November 10, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing
November 7, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
November 7, 2025
·
2 min read
·
Tristan Manalac
